The sell-off started last night and continued in after-hours trading after the New York-based biopharma company revealed that ...

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's gene therapy for the rare ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

The microbial therapeutic products market is forecast to grow from USD 17.11 billion in 2022 to USD 30.55 billion by 2030, ...

Roche inks agreement to acquire clinical-stage biopharma company, Poseida Therapeutics: Basel Wednesday, November 27, 2024, 09:00 Hrs [IST] Roche announced that it has entered int ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The following is a summary of “Prophylactic versus restrictive platelet transfusion strategy in patients with haematological malignancies in the ICU setting, a propensity-score analysis,” published in ...

LAGOS, Nigeria -/African Media Agency (AMA)/-The African Medical Centre of Excellence (AMCE) has chosen SAP and Converge Solutions as its technology partners to deliver a cutting-edge Hospital ...

Zurich: Swiss Pharmaceutical giant Roche said on Tuesday it has agreed to buy US biopharm firm Poseida Therapeutics for $1.5 ...

Roche said it will acquire biopharmaceutical company Poseida Therapeutics in a deal worth up to $1.5 billion. The pharmaceutical company said Tuesday that it has entered into a definitive merger ...

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across ...

Global biopharmaceutical company Takeda is deepening collaboration with stakeholders to deliver innovative healthcare ...